Toray Develops Porous Fibers that Adsorb Pathogenic Substances of Intractable Diseases
Toray has developed a technology to control the pore size of PMMA porous fibers up to 1,000nm, enabling the selective removal of large-molecule pathogenic substances. This innovation offers a new blood purification treatment option for intractable diseases such as autoimmune disorders and cancer.
📋 Article Processing Timeline
- 📰 Published: March 26, 2026 at 18:20
- 🔍 Collected: March 28, 2026 at 21:59 (51h 39m after Published)
- 🤖 AI Analyzed: April 15, 2026 at 03:22 (413h 23m after Collected)
Toray Industries, Inc. has announced the development of a technology that allows arbitrary control of pore diameters in polymethyl methacrylate (PMMA) porous fibers, ranging from several nanometers to approximately 1,000nm. This technological breakthrough enables the selective adsorption and removal of large-molecule pathogenic substances—such as autoantibodies, lipoproteins, and exosomes—which were previously difficult to capture. By applying this technology, Toray aims to provide new blood purification treatment options for intractable diseases, including autoimmune disorders, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer. The company is currently proceeding with the design of optimal pore sizes for specific diseases and the development of mass production technologies for early commercialization, while also exploring applications in biopharmaceutical manufacturing.
FAQ
What types of diseases can this technology treat?
It is intended for intractable diseases such as autoimmune disorders, cardiovascular metabolic diseases, neurodegenerative diseases, and cancer.
How does it differ from conventional fibers?
It can increase the pore size to up to 1,000nm, which is over 50 times larger than previous versions, allowing for the selective adsorption of large-molecule pathogenic substances.